Addressing the Challenge of Polypharmacy

Literature Cited

1. 1. 

   World Health Organ 2008. Primary health care—now more than ever World Health Rep., World Health Organ New York:
2. 2. 

   Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B 2012. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380983637–43
3. 3. 

   Ornestein SM, Nietert PJ, Jenkins RG, Litvin CB 2013. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J. Am. Board Fam. Pract. 265518–24
4. 4. 

   Scott. Gov. Polypharmacy Model Care Group 2018. Polypharmacy guidance: realistic prescribing Rep., Scott. Gov., Edinburgh . , 3rd ed.. https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/09/Polypharmacy-Guidance-2018.pdf
5. 5. 

   Köberlein J, Jürges H. 2013. Multimorbidity, incentives and the use of health services in Europe. Active Ageing and Solidarity Between Generations in Europe: First Results from SHARE After the Economic Crisis A Börsch-Supan, M Brandt, H Litwin, G Weber 243–52 Berlin: de Gruyter
6. 6. 

   Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW 2012. Adapting clinical guidelines to take account of multimorbidity. BMJ 345e6341
7. 7. 

   Shippee ND, Shah ND, May CR, Mair FS, Montori VM 2012. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J. Clin. Epidemiol. 65101041–51
8. 8. 

   Duerden M, Avery T, Payne R 2013. Polypharmacy and Medicines Optimization: Making It Safe and Sound London: The King's Fund
9. 9. 

   Payne RA, Avery AJ. 2011. Polypharmacy: one of the greatest prescribing challenges in general practice. Br. J. Gen. Pract. 6158383–84
10. 10. 

    IMS Inst. Healthc. Inform 2012. Advancing the responsible use of medicines: applying levers for change Rep., IMS Inst. Healthc. Inform. Parsippany, NJ: http://pharmanalyses.fr/wp-content/uploads/2012/10/Advancing-Responsible-Use-of-Meds-Report-01-10-12.pdf
11. 11. 

    Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D et al. 2013. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy 338827–37
12. 12. 

    World Health Organ 2017. Medication without harm Glob. Patient Saf. Chall., World Health Organ Geneva:
13. 13. 

    Mair A. 2019. Medication safety in polypharmacy, Third Global Patient Safety Challenge Rep., World Health Organ Geneva:
14. 14. 

    Mair A, Fernandez-Limos F, Alonso A, Harrison C, Hurding S et al. 2017. Polypharmacy management by 2030: a patient safety challenge Rep., SIMPATHY Consort., Coimbra, Port. http://www.simpathy.eu/sites/default/files/Managing_polypharmacy2030-web.pdf
15. 15. 

    SIMPATHY 2017. SIMPATHY economic tool Econ. Tool, SIMPATHY Consort., Scotl. http://www.simpathy.eu/resources/change-management
16. 16. 

    Scott. Gov. Model Care Polypharmacy Work. Group 2012. Polypharmacy guidance Guidance, Scott. Gov Edinburgh:. , 1st ed..
17. 17. 

    Scott. Gov. Model Care Polypharmacy Work. Group 2015. Polypharmacy guidance Guidance, Scott. Gov Edinburgh:. , 2nd ed.. https://www.sehd.scot.nhs.uk/publications/DC20150415polypharmacy.pdf
18. 18. 

    Hanlon JT, Schmader KE. 2013. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging 3011893–900
19. 19. 

    Burt J, Elmore N, Campbell SM, Rodgers S, Avery AJ, Payne RA 2018. Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. BMC Med 1691
20. 20. 

    Avery A, Bell G. 2019. Rationalising medications through deprescribing. BMJ 3641570
21. 21. 

    World Health Organ 2006. Quality of care: a process for making strategic choices in health systems Rep., World Health Organ. Geneva:
22. 22. 

    Laupacis A, Sackett D, Roberts R 1988. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 318261728–33
23. 23. 

    Cook R, Sackett D. 1995. The number needed to treat: a clinically useful measure of treatment effect. BMJ 3106977452–54
24. 24. 

    Rawlins MD, Thompson JW. 1977. Pathogenesis of adverse drug reactions. Textbook of Adverse Drug Reactions DM Davies 10–17 Oxford, UK: Oxford Univ. Press
25. 25. 

    Dumbreck S, Flynn A, Nairn M et al. 2015. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 350h949
26. 26. 

    Lindblad C, Hanlon J, Gross C et al. 2006. Clinically important drug-disease interactions and their prevalence in older adults. Clin. Ther. 2881133–43
27. 27. 

    Taber DJ et al. 2014. Clinical and economic outcomes associated with medication errors in kidney transplantation. Clin. J. Am. Soc. Nephrol. 95960–66
28. 28. 

    Hayward KL et al. 2016. Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. BMC Gastroenterol 16114
29. 29. 

    Chang Y-P, Huang S-K, Tao P et al. 2012. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrol 13196
30. 30. 

    Sutaria A, Lui L, Ahmed Z 2016. Multiple medication (polypharmacy) and chronic kidney disease in patients aged 60 and older: a pharmacoepidemiologic perspective. Ther. Adv. Cardiovasc. Dis. 104242–50
31. 31. 

    Pirmohamed M, James S, Meakin S, Green C, Scott AK et al. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329745615–19
32. 32. 

    Clin. Excell. Comm 2018. Medication safety and quality: high-risk medicines Rep., Clin. Excell. Comm Sydney: http://www.cec.health.nsw.gov.au/patient-safety-programs/medication-safety/high-risk-medicines
33. 33. 

    Health Qual. Saf. Comm. New Zealand 2014. High-risk medicines must be treated with respect—new campaign News Release, Oct. 16. https://www.hqsc.govt.nz/news-and-events/news/1814/
34. 34. 

    Natl. Pat. Saf. Agency 2011. High risk drugs list Natl. Pat. Saf. Agency London: https://www.mpft.nhs.uk/services/pharmacy/high-risk-drugs
35. 35. 

    Inst. Safe Med. Pract. Canada 2018. ISMP high-alert medications. Institute for Safe Medication Practices Canada https://www.ismp.org/assessments/high-alert-medications
36. 36. 

    Geri-EM 2013. High-risk medications. Geri-EM https://geri-em.com/medication-management/high-risk-medications
37. 37. 

    SA Health 2019. High risk medicines. Government of South Australia https://www.sahealth.sa.gov.au/wps/wcm/connect/public%20content/sa%20health%20internet/clinical%20resources/clinical%20topics/medicines%20and%20drugs/high%20risk%20medicines/high%20risk%20medicines
38. 38. 

    Dreischulte T, Donnan P, Grant A, Hapca A, McCowan C, Guthrie B 2016. Safer prescribing—a trial of education, informatics, and financial incentives. N. Engl. J. Med. 374111053–64
39. 39. 

    Howard R, Avery A, Slavenburg S, Royal S, Pipe G et al. 2007. Which drugs cause preventable admissions to hospital? A systematic review. Br. J. Clin. Pharmacol. 632136–47
40. 40. 

    Am. Geriatr. Soc. Beers Criteria Update Expert Panel 2015. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in adults. J. Am. Geriatr. Soc 632227–46
41. 41. 

    O'Mahony D, O'Sullivan D, Bryne S et al. 2015. STOPP/ START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 442213–18
42. 42. 

    Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J et al. 2015. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 725438–45
43. 43. 

    Banerjee S. 2009. The use of antipsychotic medication for people with dementia: time for action. London: Dep. Health
44. 44. 

    Ment. Welf. Comm. Scotl 2014. Dignity and respect: dementia continuing care visits Visit Rep., Ment. Welf. Comm. Scotl. Edinburgh:
45. 45. 

    Nazareth K, Burkhard K. 2016. Hypnotics & anxiolytics practice guide Pract. Guide, All Wales Med. Strateg. Group. Cardiff: http://www.wales.nhs.uk/sites3/Documents/582/Guide_Hypnotics%20%26%20Anxiolytics%20Practice%20Guide_version02.pdf
46. 46. 

    Campbell AJ, Robertson MC, Gardner MM et al. 1999. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J. Am. Geriatr. Soc. 47850–53
47. 47. 

    BNF 2018. Antidepressants London: Pharmaceutical Press
48. 48. 

    Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR et al. 2016. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 736721–32
49. 49. 

    Sumukadas D, McMurdo M, Mangoni A, Guthrie B 2013. Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data. Age Ageing 434515–21
50. 50. 

    Durán C, Azermai M, Vander Stichele R 2013. Systematic review of anticholinergic risk scales in older adults. Eur. J. Clin. Pharmacol. 6971485–96
51. 51. 

    Nishtala P, Salahudeen M, Hilmer S 2016. Anticholinergics: theoretical and clinical overview. Expert Opin. Drug Saf. 156753–68
52. 52. 

    Bishara D, Harwood D, Sauer J, Taylor D 2016. Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. Int. J. Geriatr. Psychiatry 326650–56
53. 53. 

    Chew M, Mulsant B, Pollock B, Lehman M, Greenspan A et al. 2008. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc. 5671333–41
54. 54. 

    Ehrt U, Broich K, Larsen J, Ballard C, Aarsland D 2009. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J. Neurol. Neurosurg. Psychiatry 812160–65
55. 55. 

    Rudolph J. 2008. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch. Intern. Med. 1685508–13
56. 56. 

    Sittironnarit G, Ames D, Bush A, Faux N, Flicker L et al. 2011. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement. Geriatr. Cogn. Disord. 313173–78
57. 57. 

    Eff. Prescr. Ther 2018. Quality prescribing for chronic pain Scott. Gov., Edinburgh: https://www.therapeutics.scot.nhs.uk/pain/
58. 58. 

    Pub. Health Engl 2014. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin Fact Sheet, Pub. Health Engl London: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/385791/PHE-NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf
59. 59. 

    Wills S. 2005. Drugs of Abuse London: Pharmaceutical Press. , 2nd ed..
60. 60. 

    Fac. Pain Med 2019. Crime survey for England and Wales Rep., Royal Coll Anaesth., London: https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware/clinical-use-of-opioids/crime-survey-findings
61. 61. 

    Eff. Prescr. Ther 2019. Opioid prescribing for chronic pain in primary care Rep., Scott. Gov Edinburgh:
62. 62. 

    Eff. Prescr. Ther 2019. Gabapentoid prescribing for chronic pain in primary care—resource for clinicians and boards v1.0 Quick Ref. Guide, Scott. Gov Edinburgh: https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/11/Gabapentinoid-Quick-Reference-Guide-23112018-Final-v1.0.pdf
63. 63. 

    Qaseem A, Wilt T, Kansagara D, Horwitch C, Barry M, Forciea M 2018. Haemoglobin A_1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann. Intern. Med. 1688569–76
64. 64. 

    Healthc. Improv. Scotl 2017. SIGN 116: management of diabetes—a national clinical guideline Natl. Clin. Guidel., Scott. Intercoll. Guidel. Netw. Edinburgh: https://www.sign.ac.uk/assets/sign116.pdf
65. 65. 

    O'Loughlin JL, Robitaille Y, Boivin JF, Suissa S 1993. Incidence of and risk factors for falls and injurious falls among the community dwelling elderly. Am. J. Epidemiol. 137342–54
66. 66. 

    Tinetti ME, Speechley M, Ginter SF 1988. Risk factors for falls among the elderly persons living in the community. N. Engl. J. Med. 3191701–7
67. 67. 

    NICE (Natl. Inst. Health Care Excell.) 2013. Falls in older people: assessing risk and prevention NICE Clin. Guidel., Natl. Inst. Health Care Excell. London: http://www.nice.org.uk/Guidance/CG161
68. 68. 

    World Health Organ 2015. World report on ageing and health Rep., World Health Organ. Luxembourg:
69. 69. 

    Deanrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C et al. 2010. Risk factors for falls in community-dwelling older people. Epidemiology 21658–68
70. 70. 

    Darowski A, Chambers SCF, Chambers DJ 2009. Antidepressants and falls. Drugs Aging 265381–94
71. 71. 

    Darowski A, Whiting R. 2011. Cardiovascular drugs and falls. Rev. Clin. Gerontol. 212170–79
72. 72. 

    Laflamme L, Monárrez-Espino J, Johnell K et al. 2015. Type, number or both? A population-based matched case-control study on the risk of fall injuries among older people and number of medications beyond fall-inducing drugs. PLOS ONE 103e0123390
73. 73. 

    Ryan-Atwood TE, Hutchinson-Kern M, Ilomäki J et al. 2017. Medication use and fall-related hospital admissions from long-term care facilities: a hospital-based case-control study. Drugs Aging 348625–33
74. 74. 

    Van der Velde N, van den Meiracker AH, Pols HA et al. 2007. Withdrawal of fall-risk-increasing drugs in older persons: effect on tilt-table test outcomes. J. Am. Geriatr. Soc. 55734–39
75. 75. 

    Seppala LJ, Wermelink A, de Vries M, Ploegmakers KJ, van de Glind EMM 2018. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. psychotropics. J. Am. Med. Dir. Assoc. 194371 e311–371.e317
76. 76. 

    Seppala LJ, van de Glind EMM, Daams JG, Ploegmakers KJ, de Vries M 2018. Fall-risk-increasing drugs: a systematic review and meta-analysis: III. others. J. Am. Med. Dir. Assoc. 194372.e371–372.e378
77. 77. 

    de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T 2018. Fall-risk-increasing drugs: a systematic review and meta-analysis: I. cardiovascular drugs. J. Am. Med. Dir. Assoc. 194371.e371–79
78. 78. 

    Freeland KN, Thompson AN, Zhao Y, Leal JE, Mauldin PD, Moran WP 2012. Medication use and associated risk of falling in a geriatric outpatient population. Ann. Pharmacother. 4691188–92
79. 79. 

    Dutta R. 2014. Falls in older people. Guidel. Pract. 17652–59
80. 80. 

    Elliott R. 2009. Non-adherence to medicines: not solved but solvable. J. Health Serv. Res. Policy 14158–61
81. 81. 

    PGEU (Pharm. Group Eur. Union) 2008. Targeting adherence: improving patient outcomes in Europe through community pharmacists’ intervention Policy Statement, Pharm. Group Eur Union, Brussels: https://healthwatch.eu/artikelen/PGEU_Targeting%20Adherence_2008.pdf
82. 82. 

    Eur. Comm 2019. European innovation partnership on active and healthy ageing. European Commission https://ec.europa.eu/eip/ageing/home_en
83. 83. 

    Health Lit. Place 2019. Teach back. Health Literacy Place http://www.healthliteracyplace.org.uk/tools-and-techniques/techniques/teach-back
84. 84. 

    Saum KU, Schottker B, Meid AD, Holleczek B, Haefeli WE et al. 2017. Is polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J. Am. Geriatr. Soc. 652e27–32
85. 85. 

    König M, Spira D, Demuth I, Steinhagen-Thiessen E, Norman K 2018. Polypharmacy as a risk factor for clinically relevant sarcopenia: results from Berlin ageing study. J. Gerontol. 73117–22
86. 86. 

    Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K 2013. Frailty in elderly people. Lancet 381752–62
87. 87. 

    Clegg A, Bates C, Young J, Ryan R, Nichols L et al. 2016. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing 453353–60
88. 88. 

    Benetos A, Labat C, Rossignol P, Fay R, Rolland Y et al. 2015. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents. JAMA Intern. Med. 1756989–95
89. 89. 

    Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J et al. 2010. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch. Intern. Med. 170161433–41
90. 90. 

    Boyd C, Fortin M 2010. Future of multimorbidity research: how should understanding of multimorbidity inform health systems designs. ? Public Health Rev 32451–74
91. 91. 

    van den Bussche H, Schön G, Kolonko T, Hansen H, Wegscheider K et al. 2011. Patterns of ambulatory medical care utilisation in elderly patients with special reference to chronic disease and multimorbidity—results from a claims data based observational study in Germany. BMC Geriatr 1154
92. 92. 

    Panagioti M, Stokes J, Esmail A, Coventry P, Cheraghi-Sohi S et al. 2015. Multimorbidity and patient safety incidents in primary care: a systematic review and meta-analysis. PLOS ONE 108e0135947
93. 93. 

    Shah BM, Hajjar ER. 2012. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin. Geriatr. Med. 282173–86
94. 94. 

    Davies EA, O'Mahony MS. 2015. Adverse drug reactions in special populations—the elderly. Br. J. Clin. Pharmacol. 804796–807
95. 95. 

    Hubbard RE, O'Mahony MS, Woodhouse KW 2013. Medication prescribing in frail older people. Eur. J. Clin. Pharmacol. 693319–26
96. 96. 

    Molokhia M, Majeed A. 2017. Current and future perspectives on the management of polypharmacy. BMC Fam. Pract. 1870
97. 97. 

    Pronovost PJ, Ravitz AD, Stoll RA, Kennedy SB 2015. Transforming patient safety: a sector-wide systems approach WISH Rep., Pat. Saf. Forum, Qatar Found Doha: https://www.wish.org.qa/wp-content/uploads/2018/01/WISH_PatientSafety_Forum_08.01.15_WEB-1.pdf
98. 98. 

    Peters DH. 2014. The application of systems thinking in health: Why use systems thinking. ? Health Res. Policy Syst. 1251
99. 99. 

    Stewart D, Mair A, Wilson M, Kardas P, Lewek P et al. 2016. Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opin. Drug Saf. 162203–13
100. 100. 

     McIntosh J, Alonso A, Codina A 2016. D4.1 report on case studies Rep., SIMPATHY Consort., Scotl. http://www.simpathy.eu/sites/default/files/D4_1.pdf
101. 101. 

     Mair A, Balaso A, McKenzie D, Gietona M, Weise B et al. 2015. D5.1: model change management process for managing appropriate controlling polypharmacy Rep., SIMPATHY Consort., Scotl. http://www.simpathy.eu/sites/default/files/D5_1.pdf
102. 102. 

     Cameron KS, Quinn RE. 2006. Diagnosing and Changing Organizational Culture: Based on the Competing Values Framework San Francisco: John Wiley & Sons
103. 103. 

     Deal T, Kennedy A. 2000. Corporate Cultures: The Rites and Rituals of Corporate Life New York: Perseus
104. 104. 

     Mair A, Balaso A, McKenzie D, Gietona M, Weise B et al. 2016. D5.2: model strategic plan Rep., SIMPATHY Consort., Scotl. http://www.simpathy.eu/sites/default/files/D5_2.pdf
105. 105. 

     Kotter Int 2019. Kotter's 8-step process for leading change. Kotter International https://www.kotterinc.com/8-steps-process-for-leading-change/
106. 106. 

     Mair A, Hurding S, Michael N, Kinnear M, Wilson M 2016. Case study summary Scotland (UK) Case Study, SIMPATHY Consort., Scotl. http://www.simpathy.eu/resources/case-studies/case-study-scotland
107. 107. 

     Stewart D, Gibson-Smith K, MacLure K, Mair A, Alonso A et al. 2017. A modified Delphi study to determine the level of consensus across the European Union on the structures, processes and desired outcomes of the management of polypharmacy in older people. PLOS ONE 1211e0188348
108. 108. 

     McIntosh J, Alonso A, MacLure K, Stewart D, Kempen T, Mair A 2018. A case study of polypharmacy management in nine European countries: implications for change management and implementation. PLOS ONE 134e0195232
109. 109. 

     Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F et al. 2012. The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines. J. Clin. Epidemiol. 655526–34
110. 110. 

     Bergert FW, Braun M, Ehrenthal K, Fessler J, Gross J et al. 2014. Recommendations for treating adult and geriatric patients on multimedication. Int. J. Clin. Pharmacol. Ther. 52Suppl. 11–64
111. 111. 

     Verenso 2011. Multidisciplinaire richtlijn diabetes Rep., Verenso, Utrecht. https://www.verenso.nl/_asset/_public/Richtlijnen_kwaliteit/richtlijnen/VER_Richtlijn_Diabetes_Deel2_2011_web.pdf
112. 112. 

     Scott. Gov 2017. Scottish Government events in Brussels: 2017. SIMPATHY event—27 April Scottish Government https://www.gov.scot/publications/scottish-government-events-in-brussels-2017/